Clinical trials
HER2 Positive clinical trials
Below are recruiting her2 positive clinical trials, each written for real people, not researchers. We’re tracking 344 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07095023Recruiting
Oral chemo and targeted therapy before breast cancer surgery
This trial tests a combination of an oral chemotherapy pill (paclitaxel) with two targeted antibodies (pertuzumab and trastuzumab) given before surgery for HER2-positive breast cancer. The goal is to shrink the tumor and make surgery more effective.
Beijing, Beijing MunicipalityAges 18–75 - NCT07057427RecruitingPhase 3
Nab-paclitaxel vs TCbHP for HER2-positive early breast cancer
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
Zhengzhou, HenanAges 18–70 - NCT07053085RecruitingPhase 2
Surgery or radiation for stable HER2+ breast cancer spread
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
Basking Ridge, New JerseyAges 18 years+ - NCT07008976RecruitingPhase 3
Testing TQB2102 versus standard treatment for HER2-positive advanced breast cancer
This trial tests a new drug called TQB2102 against a standard treatment (Kadcyla) for people with HER2-positive breast cancer that has spread or cannot be removed. It is for those whose cancer has worsened after previous HER2-targeted therapy.
Bengbu, AnhuiAges 18–75 - NCT07007559RecruitingPhase 2
Evorpacept with trastuzumab and chemo for HER2-positive breast cancer
This study tests an experimental drug called evorpacept when given with trastuzumab and chemotherapy for people with HER2-positive breast cancer that has spread. The goal is to see if this combination can shrink tumors or slow down the cancer.
Phoenix, ArizonaAges 18 years+ - NCT07003074RecruitingPhase 3
New drug TQB2102 vs standard therapy for HER2+ breast cancer
This trial tests a new medicine called TQB2102 against the standard combination of chemotherapy (docetaxel) plus two targeted therapies (trastuzumab and pertuzumab) for people with HER2-positive breast cancer that has come back or spread. The goal is to see if the new treatment works better and has fewer side effects.
Hefei, AnhuiAges 18–75 - NCT06938724RecruitingPhase 2
Avoiding extra surgery in women with HER2+ or triple-negative breast cancer
This trial tests whether women with HER2-positive or triple-negative breast cancer who had a complete response to chemotherapy can safely skip radiation or additional surgery. If you had a complete tumor response after chemo and had breast-conserving surgery, you may be eligible.
MilanAges 18 years+ - NCT06927180RecruitingPhase 2
Study of SHR-A1811 plus pertuzumab before surgery for HER2+ breast cancer
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
Zhengzhou, HenanAges 18–70 - NCT06928818Recruiting
T-DM1 after T-DXd for advanced HER2-positive breast cancer
This trial looks at whether a different targeted therapy, T-DM1, can work for women with advanced HER2-positive breast cancer after they have already tried another targeted therapy called T-DXd (Enhertu). If you have progressed while on T-DXd and have not had more than three previous treatments for advanced cancer, you may be able to join.
SeoulAges 19 years+ - NCT06892093Recruiting
Probiotics to prevent diarrhea from neratinib in breast cancer
This trial tests whether taking probiotics can help prevent diarrhea caused by the breast cancer drug neratinib. If you are a woman with HER2-positive breast cancer and are about to start neratinib, this study may help manage a common side effect.
Guangzhou, GuangdongAges 18 years+ - NCT06843681Enrolling by invitationPhase 2
Trastuzumab and Chemo Before Surgery for HER2-Positive DCIS
This trial tests giving trastuzumab (a targeted drug) plus a chemotherapy drug called a taxane before surgery for women with HER2-positive ductal carcinoma in situ (DCIS), an early form of breast cancer. The goal is to see if this combination can shrink or eliminate the cancer before surgery.
Guangzhou, GuangdongAges 18–70 - NCT06821490Enrolling by invitation
TAD biopsy for HER2+ breast cancer with positive lymph nodes
This trial tests the accuracy of a targeted axillary dissection (TAD) after chemotherapy in people with HER2+ breast cancer that has spread to the lymph nodes. It aims to see if the TAD method can correctly identify which lymph nodes are cancer-free before surgery.
Valencia, ValenciaAges 18 years+ - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT06731478RecruitingPhase 3
New drug combo for first treatment of HER2-positive stomach cancer
This trial tests a new targeted drug (TDXd) combined with chemotherapy, pembrolizumab, and trastuzumab for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if this combination works better than standard treatments as a first therapy.
New Haven, ConnecticutAges 18 years+ - NCT06730373RecruitingPhase 2
RC48 plus immunotherapy and chemotherapy for advanced stomach cancer
This study tests a combination of three treatments for advanced stomach cancer that is HER2-positive. The treatments are RC48, an antibody-drug conjugate that targets HER2 on cancer cells, sintilimab, which helps the immune system fight cancer, and S-1, a chemotherapy drug. The goal is to see if the combination is safe and effective as a first-line treatment.
Zhengzhou, HenanAges 18–75 - NCT06686394RecruitingPhase 1/Phase 2
Patritumab deruxtecan combinations for advanced HER2-positive breast cancer
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
Aurora, ColoradoAges 18 years+ - NCT06589830RecruitingPhase 2
TL938 with Trastuzumab for HER2+ Colorectal Cancer
This trial is testing a new combination of drugs (TL938 and trastuzumab) for people with a specific type of advanced colorectal cancer that is HER2-positive and RAS wild-type. It may offer a new option if you have already tried standard chemotherapy and a blood vessel-blocking drug.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06557057Recruiting
Aromatase inhibitors and diabetes risk in breast cancer
This study looks at how aromatase inhibitors, a type of hormone therapy for breast cancer, affect blood sugar and diabetes risk. It compares women taking these drugs to those on tamoxifen or healthy women, to see if there are changes in glucose control.
Rochester, MinnesotaAges Any age - NCT05900206RecruitingPhase 2
Trastuzumab deruxtecan vs standard chemotherapy before breast surgery
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
MalmöAges 18 years+ - NCT06532006RecruitingPhase 3
HLX22 plus trastuzumab and chemo for HER2+ stomach cancer
This trial tests adding a new drug, HLX22, to the standard combination of trastuzumab and chemotherapy for people with HER2-positive stomach or gastroesophageal junction cancer that hasn't been treated yet. The goal is to see if this three-drug mix works better than the usual two-drug approach.
Anaheim, CaliforniaAges 18 years+ - NCT06504732RecruitingPhase 2/Phase 3
IAH0968 plus CAPEOX for HER2-positive gastric cancer
This trial tests a new drug (IAH0968) combined with chemotherapy (CAPEOX) for people with HER2-positive stomach or gastroesophageal junction cancer that has not been treated before or has spread.
Harbin, HeilongjiangAges 18–75 - NCT06481956Enrolling by invitationPhase 2
T-DM1 plus a CDK4/6 inhibitor (ribociclib) for HER2-positive breast cancer
This clinical trial tests a combination of two targeted therapies for people with HER2-positive breast cancer that has spread or come back. The goal is to see if adding ribociclib to T-DM1 is safe and effective after other treatments have been used.
Hangzhou, ZhejiangAges 18–75 - NCT06441890RecruitingPhase 2
Personalized chemo before breast cancer surgery
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Chicago, IllinoisAges 18 years+ - NCT06431490RecruitingPhase 1/Phase 2
Testing TQB2102 for HER2-positive bile duct cancer
This trial tests a new drug, TQB2102, for people with advanced bile duct cancer that has HER2 protein markers. It aims to see if the drug can help when previous treatments haven't worked.
Fuyang, AnhuiAges 18–75
Hear when a new HER2 Positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 positive?
- Yes. Clin2 currently lists 344 recruiting her2 positive studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 positive trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 positive trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.